Current advances in HIV vaccine preclinical studies using Macaque models

被引：14

作者：

Liang, Binhua ^{[1
,2
]}

Li, Hongzhao ^{[3
]}

Li, Lin ^{[1
]}

Omange, Robert Were ^{[3
]}

Hai, Yan ^{[3
]}

Luo, Ma ^{[1
,3
]}

机构：

[1] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada

[2] Univ Manitoba, Biochem & Med Genet, Winnipeg, MB, Canada

[3] Univ Manitoba, Med Microbiol & Infect Dis, Winnipeg, MB, Canada

来源：

VACCINE | 2019年 / 37卷 / 26期

关键词：

Vaccine; Macaque; Simian immunodeficiency virus; Repeated-low-dose challenge; Vaccine efficacy; SIMIAN IMMUNODEFICIENCY VIRUS; CD4(+) T-CELLS; RHESUS MACAQUES; CYNOMOLGUS MACAQUES; SIV INFECTION; REVERSE-TRANSCRIPTASE; RIBONUCLEASE-ACTIVITY; GAG/POL/NEF VACCINE; SIVMAC239; INFECTION; PROTECTIVE EFFICACY;

D O I：

10.1016/j.vaccine.2019.04.094

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The macaque simian or simian/human immunodeficiency virus (SIV/SHIV) challenge model has been widely used to inform and guide human vaccine trials. Substantial advances have been made recently in the application of repeated-low-dose challenge (RLD) approach to assess SIV/SHIV vaccine efficacies (VE). Some candidate HIV vaccines have shown protective effects in preclinical studies using the macaque SIV/SHIV model but the model's true predictive value for screening potential HIV vaccine candidates needs to be evaluated further. Here, we review key parameters used in the RLD approach and discuss their relevance for evaluating VE to improve preclinical studies of candidate HIV vaccines. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.

引用

页码：3388 / 3399

页数：12

共 50 条

[21] Advances in Prophylactic HIV Vaccine Development
Michael, Nelson
Kim, Jerome
Robb, Merlin
Thomas, Rasmi
Haynes, Barton
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 67 : 59 - 59
[22] Advances in Preventive HIV Vaccine Development
Michael, Nelson L.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 : 51 - 51
[23] Current advances in HIV vaccines
D’Souza M.P.
Allen M.
Sheets R.
Johnston M.I.
Current HIV/AIDS Reports, 2004, 1 (1) : 18 - 24
[24] Developments in preclinical AIDS vaccine efficacy models
Bogers, WMJM
Cheng-Mayer, C
Montelaro, RC
AIDS, 2000, 14 : S141 - S151
[25] A control-conditional test for assessing HIV vaccine efficacy in small sample preclinical studies
Albert, JM
STATISTICS IN MEDICINE, 1996, 15 (21-22) : 2371 - 2378
[26] Current Advances in Zika Vaccine Development
Wang, Yuchen
Ling, Lin
Zhang, Zilei
Marin-Lopez, Alejandro
VACCINES, 2022, 10 (11)
[27] Enhancing efficacy of HIV Gag DNA vaccine by local delivery of GM-CSF in murine and macaque models
Song, Ruijiang
Liu, Shuqin
Adams, Robert J.
Leong, Kam W.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2006, 26 (06): : 380 - 389
[28] Current Advances in Humanized Mouse Models for Studying NK Cells and HIV Infection
Kim, Jocelyn T.
Bresson-Tan, Gabrielle
Zack, Jerome A.
MICROORGANISMS, 2023, 11 (08)
[29] MODELS OF PRECLINICAL STUDIES OF ANTHRACYCLINES
FIZAMES, C
PATHOLOGIE BIOLOGIE, 1987, 35 (01): : 41 - 48
[30] The HIV vaccine pipeline, from preclinical to phase III
Schultz, AM
Bradac, JA
AIDS, 2001, 15 : S147 - S158

← 1 2 3 4 5 →